Engineered stem cells aim to speed recovery in blood cancer patients
NCT ID NCT04260698
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests omidubicel, an experimental stem cell transplant, for people with high-risk blood cancers like leukemia or lymphoma. The goal is to see if it helps the body rebuild its immune system faster after transplant. Participants receive omidubicel along with standard transplant care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
omidubicel (stem cell transplant)
What this could lead to
If successful, omidubicel could help patients with blood cancers recover their immune system faster after a stem cell transplant, potentially reducing complications.
What could go wrong
This is an early expanded access study with a small number of participants. The treatment may not work for everyone, and stem cell transplants carry risks like infection and graft failure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Loyola University, Cardinal Bernardin Cancer Center
Maywood, Illinois, 60153, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Stanford University Cancer Institute
Palo Alto, California, 94063, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States